thiorphan has been researched along with Blood Pressure, High in 20 studies
Thiorphan: A potent inhibitor of membrane metalloendopeptidase (ENKEPHALINASE). Thiorphan potentiates morphine-induced ANALGESIA and attenuates naloxone-precipitated withdrawal symptoms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effect of prolonged administration of a carboxypeptidase Y-like kininase inhibitor, ebelactone B (EB) (2-ethyl-3, 11-dihydroxy-4, 6, 8, 10, 12-pentamethyl-9-oxo-6-tetradecenoic 1, 3-lactone), on the development of deoxycorticosterone acetate (DOCA)-salt hypertension was tested." | 7.70 | Effect of prolonged administration of a urinary kinase inhibitor, ebelactone B on the development of deoxycorticosterone acetate-salt hypertension in rats. ( Hayashi, I; Ito, H; Izumi, T; Katori, M; Majima, M; Nakajima, S, 1999) |
| "Cyclosporine (CysA), a potent immunosuppressant, is associated with hypertension and nephrotoxicity." | 7.70 | Effects of chronic neutral endopeptidase inhibition in rats with cyclosporine-induced hypertension. ( Fujimura, A; Furukawa, K; Inaba, S; Mabuchi, H; Miyamori, I; Takeda, Y, 2000) |
| "The ability of sinorphan (100 mg twice a day) to lower blood pressure was compared with that of the angiotensin converting enzyme (ACE) inhibitor captopril (25 mg twice a day) using a randomized-sequence, double-blind crossover design in 16 patients with essential hypertension." | 5.08 | Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension. ( Brouard, R; Brunner, HR; Burnier, M; Favrat, B; Lecomte, JM; Nussberger, J; Waeber, B, 1995) |
| "The effect of prolonged administration of a carboxypeptidase Y-like kininase inhibitor, ebelactone B (EB) (2-ethyl-3, 11-dihydroxy-4, 6, 8, 10, 12-pentamethyl-9-oxo-6-tetradecenoic 1, 3-lactone), on the development of deoxycorticosterone acetate (DOCA)-salt hypertension was tested." | 3.70 | Effect of prolonged administration of a urinary kinase inhibitor, ebelactone B on the development of deoxycorticosterone acetate-salt hypertension in rats. ( Hayashi, I; Ito, H; Izumi, T; Katori, M; Majima, M; Nakajima, S, 1999) |
| "Cyclosporine (CysA), a potent immunosuppressant, is associated with hypertension and nephrotoxicity." | 3.70 | Effects of chronic neutral endopeptidase inhibition in rats with cyclosporine-induced hypertension. ( Fujimura, A; Furukawa, K; Inaba, S; Mabuchi, H; Miyamori, I; Takeda, Y, 2000) |
| "DOCA-salt hypertension was induced in both BN-Ka and Brown Norway Kitasato (BN-Ki) rats after left nephrectomy." | 1.30 | Effects of a neutral endopeptidase inhibitor, BP102, on the development of deoxycorticosterone acetate-salt hypertension in kininogen-deficient Brown Norway Katholiek rats. ( Hayashi, I; Ito, H; Katori, M; Majima, M; Nakajima, S; Yajima, Y, 1998) |
| "Thiorphan was administered intravenously (i." | 1.29 | Disposition of thiorphan in DOCA-salt and spontaneously hypertensive rats. ( Berry, C; Ghai, RD; Hopkins, MF; Sakane, Y; Singh, K, 1993) |
| "Bradykinin plays a permissive role in the diuretic responses to atrial natriuretic factor and inhibitors of neutral metalloendopeptidase." | 1.28 | Neutral metalloendopeptidase inhibitors as ANF potentiators: sites and mechanisms of action. ( Chiu, PJ; Sybertz, EJ; Vemulapalli, S; Watkins, RW, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 18 (90.00) | 18.2507 |
| 2000's | 2 (10.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stanton, JL | 1 |
| Sperbeck, DM | 1 |
| Trapani, AJ | 2 |
| Cote, D | 1 |
| Sakane, Y | 3 |
| Berry, CJ | 1 |
| Ghai, RD | 4 |
| Beil, ME | 1 |
| Coté, DT | 1 |
| de Lombaert, S | 1 |
| Erion, MD | 1 |
| Gerlock, TE | 1 |
| Hopkins, MF | 2 |
| Peppard, JV | 1 |
| Webb, RL | 1 |
| Favrat, B | 1 |
| Burnier, M | 1 |
| Nussberger, J | 1 |
| Lecomte, JM | 2 |
| Brouard, R | 1 |
| Waeber, B | 1 |
| Brunner, HR | 1 |
| Pham, I | 3 |
| Lévy, B | 1 |
| Fournié-Zaluski, MC | 3 |
| Poitevin, P | 1 |
| Roques, BP | 2 |
| Michel, JB | 3 |
| Hirata, Y | 1 |
| Suzuki, Y | 1 |
| Suzuki, E | 1 |
| Hayakawa, H | 1 |
| Kimura, K | 1 |
| Goto, A | 1 |
| Omata, M | 1 |
| Minamino, N | 1 |
| Kangawa, K | 1 |
| Matsuo, H | 1 |
| Berry, C | 2 |
| Singh, K | 1 |
| Wilkins, MR | 1 |
| Gonzalez, W | 1 |
| Doucet, J | 1 |
| Wegner, M | 1 |
| Ganten, D | 1 |
| Stasch, JP | 1 |
| Vishwanatha, JK | 1 |
| Davis, RG | 1 |
| Blumberg, S | 1 |
| Gao, XP | 1 |
| Rubinstein, I | 1 |
| Nakajima, S | 2 |
| Majima, M | 2 |
| Ito, H | 2 |
| Hayashi, I | 2 |
| Yajima, Y | 1 |
| Katori, M | 2 |
| Ferro, CJ | 1 |
| Spratt, JC | 1 |
| Haynes, WG | 1 |
| Webb, DJ | 1 |
| Izumi, T | 1 |
| Pamnani, MB | 1 |
| Chen, S | 1 |
| Bryant, HJ | 1 |
| Schooley, JF | 1 |
| Haddy, FJ | 1 |
| Takeda, Y | 1 |
| Inaba, S | 1 |
| Furukawa, K | 1 |
| Fujimura, A | 1 |
| Miyamori, I | 1 |
| Mabuchi, H | 1 |
| el Amrani, AI | 1 |
| Corvol, P | 1 |
| Roques, B | 1 |
| Schulz, R | 1 |
| Ghai, R | 1 |
| Sybertz, EJ | 1 |
| Chiu, PJ | 1 |
| Watkins, RW | 1 |
| Vemulapalli, S | 1 |
| Lefrançois, P | 1 |
| Clerc, G | 1 |
| Duchier, J | 1 |
| Lim, C | 1 |
| Gros, C | 1 |
| Schwartz, JC | 1 |
1 review available for thiorphan and Blood Pressure, High
| Article | Year |
|---|---|
Clinical potential of endopeptidase-24.11 inhibitors in cardiovascular disease.
Topics: Animals; Antihypertensive Agents; Cardiovascular Diseases; Cyclohexanecarboxylic Acids; Diuretics; D | 1993 |
3 trials available for thiorphan and Blood Pressure, High
| Article | Year |
|---|---|
Neutral endopeptidase versus angiotensin converting enzyme inhibition in essential hypertension.
Topics: Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Factor; Blood Pressure; Ca | 1995 |
Inhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivo.
Topics: Adult; Aldosterone; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Atrial Natriuretic Fac | 1998 |
Antihypertensive activity of sinorphan.
Topics: Aged; Blood Pressure; Clinical Trials as Topic; Drug Administration Schedule; Drug Evaluation; Femal | 1990 |
16 other studies available for thiorphan and Blood Pressure, High
| Article | Year |
|---|---|
Heterocyclic lactam derivatives as dual angiotensin converting enzyme and neutral endopeptidase 24.11 inhibitors.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Cysteine; Hypertension; | 1993 |
Pharmacologic profile of CGS 24128, a potent, long-acting inhibitor of neutral endopeptidase 24.11.
Topics: Amino Acid Sequence; Animals; Atrial Natriuretic Factor; beta-Alanine; Blood Pressure; Desoxycortico | 1994 |
Acute hemodynamic effects of combined inhibition of neutral endopeptidase and angiotensin converting enzyme in spontaneously hypertensive rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Drug Therapy, Combination; Enalap | 1995 |
Mechanisms underlying the augmented responses of deoxycorticosterone acetate-salt hypertensive rats to neutral endopeptidase inhibitors.
Topics: Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Base Sequence; Blood Pressure; Desoxyco | 1994 |
Disposition of thiorphan in DOCA-salt and spontaneously hypertensive rats.
Topics: Animals; Desoxycorticosterone; Hypertension; Male; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Rats, S | 1993 |
Effects of angiotensin-converting enzyme and neutral endopeptidase inhibitors: influence of bradykinin.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Bradykinin; Cyclic GMP; Enalapril | 1996 |
Neutral endopeptidase inhibition potentiates the effects of natriuretic peptides in renin transgenic rats.
Topics: Animals; Animals, Genetically Modified; Atrial Natriuretic Factor; Blood Pressure; Cyclic GMP; Disea | 1996 |
Increased tissue neutral endopeptidase 24.11 activity in spontaneously hypertensive hamsters.
Topics: Animals; Anions; Chlorides; Cricetinae; Glycopeptides; Hypertension; Kidney; Neprilysin; Osmolar Con | 1998 |
Effects of a neutral endopeptidase inhibitor, BP102, on the development of deoxycorticosterone acetate-salt hypertension in kininogen-deficient Brown Norway Katholiek rats.
Topics: Administration, Oral; Animals; Atrial Natriuretic Factor; Desoxycorticosterone; Drug Administration | 1998 |
Effect of prolonged administration of a urinary kinase inhibitor, ebelactone B on the development of deoxycorticosterone acetate-salt hypertension in rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Bradykin | 1999 |
Ecadotril. (S)-acetorphan, sinorphan.
Topics: Animals; Cardiovascular Diseases; Drugs, Investigational; Endopeptidases; Heart Failure; Humans; Hyp | 1999 |
Effects of a neutral endoprotease enzyme inhibitor, thiorphan, on hemodynamics and renal excretory function in four models of experimental hypertension.
Topics: Animals; Atrial Natriuretic Factor; Biomarkers; Blood Pressure; Cyclic GMP; Hypertension; Infusions, | 2000 |
Effects of chronic neutral endopeptidase inhibition in rats with cyclosporine-induced hypertension.
Topics: Animals; Blood Pressure; Blotting, Southern; Cyclosporine; DNA Probes; Endothelin-1; Endothelium, Va | 2000 |
Effects of the selective neutral endopeptidase inhibitor, retrothiorphan, on renal function and blood pressure in conscious normotensive Wistar and hypertensive DOCA-salt rats.
Topics: Animals; Atrial Natriuretic Factor; Blood Pressure; Bradykinin; Cyclic GMP; Desoxycorticosterone; Di | 1992 |
Characterisation of neutral endopeptidase 3.4.24.11 (NEP) in the kidney: comparison between normotensive, genetically hypertensive and experimentally hypertensive rats.
Topics: Animals; Body Weight; Desoxycorticosterone; DNA; Glycopeptides; Hot Temperature; Hydrogen-Ion Concen | 1991 |
Neutral metalloendopeptidase inhibitors as ANF potentiators: sites and mechanisms of action.
Topics: Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Blood Pressure; Bradykinin; Desoxycorti | 1991 |